Comparative Pharmacology
Head-to-head clinical analysis: CALCIPOTRIENE versus VECTICAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIPOTRIENE versus VECTICAL.
CALCIPOTRIENE vs VECTICAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.
VECTICAL (calcitriol) is a vitamin D analog that binds to vitamin D receptors (VDRs) in target tissues, increasing intestinal calcium absorption, renal calcium reabsorption, and enhancing osteoclast activity to mobilize calcium from bone, thereby raising serum calcium levels.
Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.
1-2 mcg orally twice daily, increased every 2-4 weeks based on serum calcium and PTH levels. Maximum dose: 4 mcg twice daily.
None Documented
None Documented
The terminal elimination half-life of calcipotriene is approximately 5–6 hours following topical application. Systemic clearance is rapid due to extensive hepatic metabolism, leading to minimal accumulation.
Mean terminal elimination half-life is approximately 3.7 hours (range 2.5–5.5 hours) in healthy adults. Clinically, steady-state is achieved within 2–3 days.
Calcipotriene is rapidly metabolized in the liver to inactive metabolites; less than 1% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 70% of the administered dose, primarily as metabolites, with about 16% excreted in urine.
Primarily hepatobiliary (74%) and fecal (14%), with renal excretion accounting for <1% of the administered dose as unchanged drug. Enterohepatic recirculation occurs.
Category C
Category C
Vitamin D Analog
Vitamin D Analog